STOCKS TELEGRAPH

Tag: Nuwellis

  • Pre-Market Spike For Nuwellis After Securing New Blood Filtering Patent

    Pre-Market Spike For Nuwellis After Securing New Blood Filtering Patent

    The stock price of Nuwellis, Inc. (NASDAQ: NUWE) surged 156.71% to $17.70 during pre-market activity. The sharp rise in value, which marked a shift in the company’s technological and strategic orientation, was caused by a newly granted U.S. patent.

    Breakthrough Patent Strengthens Technological Edge

    On July 15, 2025, Nuwellis was officially issued U.S. Patent No. 12,357,734 by the U.S. Patent and Trademark Office. The patent, “Extracorporeal Blood Filtering Machine and Methods,” broadens the company’s intellectual property portfolio while resolving a chronic issue in continuous renal replacement therapy (CRRT).

    By taking into consideration differences in the density of replacement fluids and effluent—a frequently disregarded but clinically important variable—the patented approach increases the precision of fluid balance.

    A fluid density of 1 g/mL is the default for the majority of CRRT systems now in use. This simplicity can result in significant fluid imbalance mistakes. With Nuwellis’ invention, fluid density may be ascertained by derived metrics, machine measurements, or user input, allowing for more accurate volumetric flow tracking and better clinical results.

    Strategic IP Portfolio Expansion

    The inclusion of this patent is consistent with Nuwellis’ ongoing commitment to innovation. The company’s growing patent portfolio supports its mission to enhance extracorporeal fluid management and generate long-term, sustainable revenue.

    By addressing identified gaps in clinical technology, Nuwellis continues to hold its position as a pioneer in patient-centric treatment solutions. Every patent that the business has acquired not only protects its intellectual property but also greatly enhances its competitive edge and sets it apart in the marketplace.

    Strengthening of Leadership By Appointing a CEO

    In line with its strategic goals, Nuwellis recently announced the hiring of John Erb as CEO. Having held the role from 2015 to 2020 and as interim CEO since February 2025, Erb brings continuity, experience, and a new viewpoint to the role.

    The Board’s decision demonstrates its confidence in Erb’s capacity to steer the company toward future growth and operational efficiency. NUWE has already experienced a recovery in momentum and strategic clarity during his interim leadership.

  • Nuwellis, Inc. (NUWE) Climbs High with FDA Approval for Quelimmune

    Nuwellis, Inc. (Nasdaq: NUWE) saw a modest 1.83% increase in trading on Friday. However, today’s premarket session reveals a significant uptick of 10%, indicating promising developments for investors.

    Advancing Pediatric Care

    Nuwellis, a medical technology company based in Minneapolis, focuses on enhancing patient outcomes, particularly for those grappling with fluid overload. Their flagship product, the Aquadex SmartFlow® system, is designed for ultrafiltration therapy.

    In a recent announcement, Nuwellis disclosed the FDA’s granting of Humanitarian Device Exemption (HDE) to SeaStar Medical Holding Corporation (Nasdaq: ICU) for their pediatric Selective Cytopheretic Device, Quelimmune™.

    A Breakthrough in Pediatric Therapy

    Quelimmune™ targets pediatric patients weighing 10 kg or more suffering from acute kidney injury (AKI) and sepsis. This approval marks a significant milestone, potentially revolutionizing care for critically ill children. Nestor Jaramillo, Jr., Nuwellis’ CEO, emphasizes the life-saving potential of Quelimmune™, citing a 50% reduction in mortality rates observed in clinical trials.

    Eric Schlorff, CEO of SeaStar Medical, echoes Jaramillo’s sentiments, underscoring the device’s capacity to mitigate the adverse effects of cytokine storms, a common complication in critically ill patients.

    Investor Confidence and Future Prospects

    Despite skepticism, investors remain optimistic about Nuwellis’ trajectory. The company’s collaboration with esteemed medical professionals and FDA support underscores its credibility. Furthermore, discussions surrounding reverse stock splits and delisting concerns are tempered by assurances of compliance and strategic partnerships with Nuwellis’ distributor, $NUWE.

    As Nuwellis gears up for commercialization, the approval of Quelimmune™ signals a promising future, not only for the company but also for pediatric patients in dire need of innovative therapeutic solutions.

    Conclusion

    Nuwellis, Inc.’s recent achievements, particularly the FDA approval for Quelimmune™, signify a significant leap forward in pediatric medical technology. With a steadfast commitment to innovation and patient care, Nuwellis is poised for a transformative impact on the healthcare landscape.